Capricor Therapeutics, Inc. (CAPR) revenue
Capricor Therapeutics, Inc. (CAPR) reported revenue of $22.27M in fiscal 2024 (the year ended December 31, 2024). That is 11.5% lower than the $25.18M of fiscal 2023. Figures as of 18 Nov 2026, 06:39 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2024
- $22.27M
- Change on fiscal 2023
- −11.5%
- Growth, 5 years
- +85.8% a year
- Growth, 10 years
- +16.6% a year
- Highest on record
- $25.18Mfiscal 2023
- Lowest on record
- $195.50Kfiscal 2012
- Fiscal years on record
- 142011–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Capricor Therapeutics, Inc. revenue, in more detail
Over the five fiscal years to 2024 revenue grew at a compound 85.8% a year; over ten years the rate was 16.6% a year. Across the 14 fiscal years on record (2011–2024), the highest was $25.18M in fiscal 2023 and the lowest $195.50K in fiscal 2012.
Revenue by fiscal year
Capricor Therapeutics, Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2024 | $22.27M | 11.5% down | |
| 2023 | $25.18M | 886.8% up | |
| 2022 | $2.55M | 941.8% up | |
| 2021 | $244.90K | 21.1% down | |
| 2020 | $310.25K | 69.1% down | |
| 2019 | $1.01M | 39.9% down | |
| 2018 | $1.67M | 37.3% down | |
| 2017 | $2.67M | 33.3% down | |
| 2016 | $4.00M | 27.5% down | |
| 2015 | $5.52M | 15.3% up | |
| 2014 | $4.79M | 851.2% up | |
| 2013 | $503.23K | 157.4% up | |
| 2012 | $195.50K | 85.6% down | |
| 2011 | $1.35M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Capricor Therapeutics, Inc., figure by figure
- Capricor Therapeutics, Inc. market cap
- Capricor Therapeutics, Inc. earnings
- Capricor Therapeutics, Inc. earnings per share (EPS)
- Capricor Therapeutics, Inc. P/E ratio
- Capricor Therapeutics, Inc. P/S ratio
- Capricor Therapeutics, Inc. P/B ratio
- Capricor Therapeutics, Inc. free cash flow
- Capricor Therapeutics, Inc. operating margin
- Capricor Therapeutics, Inc. dividend
- Capricor Therapeutics, Inc. shares outstanding
- Capricor Therapeutics, Inc. total debt
- Capricor Therapeutics, Inc. cash on hand
- Capricor Therapeutics, Inc. total assets
- Capricor Therapeutics, Inc. return on equity (ROE)
- Capricor Therapeutics, Inc. return on invested capital (ROIC)
Capricor Therapeutics, Inc. (CAPR) overview: price, valuation and scorecard
Capricor Therapeutics, Inc. revenue: questions and answers
What is Capricor Therapeutics, Inc.'s revenue?
Capricor Therapeutics, Inc. (CAPR) reported revenue of $22.27M in fiscal 2024 (the year ended December 31, 2024). That is 11.5% lower than the $25.18M of fiscal 2023.
What is the growth rate of Capricor Therapeutics, Inc.'s revenue?
Over the five fiscal years to 2024 revenue grew at a compound 85.8% a year; over ten years the rate was 16.6% a year.
What are the highest and lowest revenue figures on record for Capricor Therapeutics, Inc.?
Across the 14 fiscal years on record (2011–2024), the highest was $25.18M in fiscal 2023 and the lowest $195.50K in fiscal 2012.
How is Capricor Therapeutics, Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Capricor Therapeutics, Inc. (CAPR) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/CAPR/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.